Jubilant Pharmova Limited, an integrated global Pharmaceuticals Company, has announced that Jubilant Pharma Limited, a material wholly-owned subsidiary of the Company, through one of its subsidiaries, Jubilant Cadista Pharmaceuticals Inc. has received Abbreviated New Drug Application (ANDA) final approval for Doxepin Hydrochloride Capsules, 10 mg, 25mg, 50mg, 75mg, and 100mg, the generic version of Sinequan®.
It is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis, the company said.
As on December 31, 2021, Jubilant’s Pharmaceuticals business had a total of 98 ANDAs for Oral Solids filed in the US, of which 61 have been approved and 4 Injectable/Opthalmic filings, of which 2 have been approved.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
